Davis Polk advised the representatives of the several underwriters in the IPO.Cyteir Therapeutics, Inc. executed the $133.2 million initial public offering of 7,400,000 shares of common stock…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
